gastrointestinal and abdominal malignant tumor
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients with histologically confirmed or clinically suspected advanced gastrointestinal or abdominal malignant tumor a: Colorectal cancer b: Gastric cancer c: Esophageal cancer d: Hepatocellular carcinoma e: Biliary tract cancer f: Pancreatic cancer g: Small intestine, Appendix or Anal canal cancer h: Neuroendocrine tumor or cancer of GI i: Gastrointestinal stromal tumor 2) Planned to receive systemic chemotherapy for malignant tumor 3) Presence or ability to acquire sufficient samples for MSI and/or MMR-IHC testing 4) Written informed consent was obtained
Exclusion criteria
Exclusion criteria: 1) Judged by the investigator to be inappropriate for study participation for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of MSI-H in advanced gastrointestinal and abdominal malignant tumor | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between MSI and MMR-IHC status and cancer genome alterations, molecular biological characteristics, clinicopathological features or prognosis | — |
Countries
Japan
Contacts
National Cancer Center Hospital East Clinical Research Support Office